Germany supply disruption unresolved
Third-party supplier disruption continues with no clear timeline for resolution; alternative supplier may take 3-4 quarters.
high · management_commentary
Torrent Pharmaceuticals Ltd — Q3 FY26
Torrent Pharma delivered a strong Q3 FY26 with 18% revenue growth to ₹3,333 crore and 19% EBITDA growth to ₹1,088 crore, driven by double-digit expansion in India (+14%) and Bra...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
JB Pharma integration disruption in Q4
Management expects Q4 to be muted due to change of control and process integration, potentially impacting sales.
medium · management_commentaryGLP-1 launch delays in Brazil
Semaglutide launch delayed to next financial year; regulatory approval timeline uncertain despite prioritization.
medium · analyst_questionUS growth dependent on launch timing and competition
US revenue growth is contingent on timely new launches and competitive landscape, which are unpredictable.
medium · management_commentary